Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes

Diabetologia

Volumn 59, Issue 6, 2016, Pages 1162-1166

  Babiker, Tarig ^a,b   Vedovato, Natascia ^c   Patel, Kashyap ^a,b   Thomas, Nicholas ^a,b   Finn, Roisin ^a,b   Männikkö, Roope ^c,d   Chakera, Ali J ^b,e   Flanagan, Sarah E ^b   Shepherd, Maggie H ^a,b   Ellard, Sian ^a,b   Ashcroft, Frances M ^c   Hattersley, Andrew T ^a,b  

^a ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

ATP sensitive potassium channel; Neonatal diabetes; Sulfonylurea receptor

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; MESSENGER RNA; SULFONYLUREA DERIVATIVE; SULFONYLUREA RECEPTOR 1; TOLBUTAMIDE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INWARDLY RECTIFYING POTASSIUM CHANNEL;

ARTICLE; BODY WEIGHT; DIABETES MELLITUS; DISEASE DURATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE MUTATION; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN TREATMENT; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE; XENOPUS; BLOOD; DRUG EFFECTS; FEMALE; GENETICS; GLUCOSE BLOOD LEVEL; INFANT; INFANT, NEWBORN, DISEASES; MALE; MULTIVARIATE ANALYSIS; MUTATION;

BLOOD GLUCOSE; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFANT; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INSULIN; MALE; MULTIVARIATE ANALYSIS; MUTATION; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS;

EID: 84962176707     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-3921-8     Document Type: Article

References (14)

1. Flanagan SE, Edghill EL, Gloyn AL et al (2006) Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia 49:1190–1197
2. Pearson ER, Flechtner I, Njølstad PR et al (2006) Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355:467–477
3. Shepherd M (2006) Transforming lives: transferring patients with neonatal diabetes from insulin to sulphonylureas. Eur Diabetes Nurs 3:137–142
4. Thurber BW, Carmody D, Tadie EC et al (2015) Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes. Diabetologia 58:1430–1435
5. ATP channel in glucose homeostasis in health and disease: more than meets the islet. J Physiol 588:3201–3209
6. World Health Organization, WHO Multicentre Growth Reference Study Group (2006) WHO Child Growth Standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. Geneva: World Health Organization. Acta Paediatr Suppl 450:76–85
7. Hattersley AT (2015) Transferring patients with diabetes due to a KIR6.2 mutation from insulin to sulphonylureas: providing information for patients and professionals on research and clinical care in genetic types of diabetes. Available from www.diabetesgenes.org/content/transferring-patients-diabetes-due-kir62-mutation-insulin-sulphonylureas, accessed 26 Jan 2015
8. Gillis KD, Gee WM, Hammoud A et al (1989) Effects of sulfonamides on a metabolite-regulated ATPi-sensitive K+ channel in rat pancreatic B-cells. Am J Physiol 257:C1119–C1127
9. Shimomura K, Flanagan SE, Zadek B et al (2009) Adjacent mutations in the gating loop of Kir6.2 produce neonatal diabetes and hyperinsulinism. EMBO Mol Med 1:166–177. doi:10.1002/emmm.200900018
10. Brereton MF, Iberl M, Shimomura K et al (2014) Reversible changes in pancreatic islet structure and function produced by elevated blood glucose. Nat Commun 5:4639. doi:10.1038/ncomms5639
11. Mlynarski W, Tarasov AI, Gach A et al (2007) Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11. Nat Clin Pract Neurol 3:640–645. doi:10.1038/ncpneuro0640
12. Shimomura K, Girard CAJ, Proks P et al (2006) Mutations at the same residue (R50) of Kir6.2 (KCNJ11) that cause neonatal diabetes produce different functional effects. Diabetes 55:1705–1712. doi:10.2337/db05-1640
13. Girard CAJ, Shimomura K, Proks P et al (2006) Functional analysis of six Kir6.2 (KCNJ11) mutations causing neonatal diabetes. Pflugers Arch Eur J Physiol 453:323–332. doi:10.1007/s00424-006-0112-3
14. O’Connell SM, Proks P, Kramer H et al (2015) The value of in vitro studies in a case of neonatal diabetes with a novel Kir6.2-W68G mutation. Clin Case Rep 3:884–887. doi:10.1002/ccr3.370